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Abstract
Tuberculosis (TB) is among the leading causes of morbidity and mortality. The causative
agent,Mycobacterium tuberculosis (Mtb), has evolved virulent factors for entry, survival,
multiplication and immune evasion. Rv2031 (also called alpha crystallin, hspX, 16-kDa anti-
gen), one of the most immunogenic latency antigens, is believed to play a key role in long-
term viability ofMtb. Here, we report the dynamics of pro-inflammatory (IFN-γ, TNF-α) and
anti-inflammatory (IL-10) cytokines against Rv2031 using whole blood assay in human co-
horts in a TB endemic setting. Cytokine responses to ESAT-6-CFP-10 were also measured
for comparison. Blood samples were collected from smear positive pulmonary TB patients
and their contacts at baseline, 6 and 12 months, and from community controls at entry. At
baseline, 54.4% of controls and 73.2% of contacts were QFT-GIT test positive. Baseline
IFN-γ, TNF-α and IL-10 responses to Rv2031 were significantly higher in controls compared
to contacts and untreated patients (p<0.001). Furthermore, untreated patients had signifi-
cantly higher TNF-α and IL-10 responses to Rv2031 compared to contacts (p<0.001). In
contacts and treated patients, IFN-γ, TNF-α and IL-10 responses to Rv2031 significantly in-
creased over 12 months (p<0.0001) and became comparable with the corresponding levels
in controls. There was a positive and significant correlation between Rv2031 and ESAT-6-
CFP-10 specific cytokine responses in each study group. The fact that the levels of IFN-γ,
TNF-α and IL-10 against Rv2031 were highest during latent TB infection may indicate their
potential as markers of protection against TB. Taken together, the findings of this study sug-
gest the potential of IFN-γ, TNF-α and IL-10 against Rv2031 as biomarkers of the host re-
sponse toMtb during convalescence from, and the absence of, active tuberculosis.
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Introduction
Tuberculosis (TB) remains a significant cause of morbidity and mortality worldwide with
9 million cases and 1.5 million deaths in 2013 alone [1]. Moreover, it is estimated that a third
of the world population is infected withMycobacterium Tuberculosis (Mtb) [2]. Such a high
rate of latent TB infection implies the presence of a huge reservoir for active TB.
Bacille Calmette Guerin (BCG), the only available TB vaccine, has highly variable efficacy
mainly limited to preventing severe forms of TB in children [3]. Therefore, there is an extensive
research to develop an efficacious vaccine to replace or augment BCG [4]. Rv2031 (also known
as alpha crystallin, hspX, 16-kDa) is among vaccine candidate proteins given increasing atten-
tion. Rv2031, an immunodominant protein, is one of the proteins expressed during latent TB
infection. It was found to be the dominantly expressed protein in stationary phase and believed
to play a key role in maintaining protein stability and long term viability ofMtb [5, 6]. The
potential of this protein as a vaccine candidate has been investigated in several animal models
[7–11] and encouraging results were reported. For example, adjunctive immunotherapy of
mice with a DNA vaccine expressing Rv2031 was shown to significantly reduce bacillary load,
shorten treatment duration, result in complete restoration of lung architecture and prevent re-
activation [10]. Similarly, in guinea pigs, Rv2031-based vaccination was shown to impart pro-
tection against TB through enhanced production of IL-12, IL-10 and TGF-β [11].
A limited number of studies investigated IFN-γ response to RV2031 in humans and re-
ported contradictory results. For example, a study from The Gambia [12] and Colombia [13]
reported increased IFN-γ response to Rv2031 in household contacts compared to community
controls whereas investigators of the VACSEL Study Group in Ethiopia and The Gambia [14]
and another independent study from Ethiopia [15] reported significantly increased IFN-γ in
community controls compared to both TB patients and contacts. Besides, previous reports
were limited to IFN-γ response to Rv2031. However, in addition to IFN-γ, other cytokines, no-
tably TNF-α, are considered to be essential for the control of TB infection [16, 17]. In addition,
IL-10 is a regulatory cytokine believed to play a key role in suppressing inflammatory and
immunopathological responses [16, 17] and hence contributing to the outcome of infection.
We, therefore, investigated the dynamics of pro-inflammatory (IFN-γ, TNF-α) and anti-in-
flammatory (IL-10) cytokine responses to Rv2031 in TB patients (before and after treatment),
their household contacts and community controls in a TB endemic setting. Results were com-
pared with cytokine responses to ESAT-6-CFP-10 (E6C10) since these antigens are believed to
be specific toMtb complex. To the best of our knowledge, this is the first longitudinal study in
human populations in an endemic setting, where pro-and anti-inflammatory cytokine re-
sponses to Rv2031 are compared in different cohorts.
Materials and Methods
Study area
This study was conducted in the capital of Ethiopia, Addis Ababa with estimated population of
2.7 million [18]. In Addis Ababa, the majority of TB patients are treated in health centers and
therefore, 7 among 24 health centers (Akaki, Kotebe, Woreda 17, Kazanchis, Shiromeda, Tekle-
hymanot and Woreda 9) with established Directly Observed Treatment, Short Course (DOTS)
services for TB were included in this study.
Study participants
From April to December 2012, smear positive pulmonary TB patients were recruited prospec-
tively from selected health centers. According to the national guideline for TB, Leprosy and
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TB/HIV [19], patients with cough lasting more than 2 weeks are screened for TB. The diagnosis
of smear positive pulmonary TB was made when at least two out of three consecutive sputum
smear examinations were positive for acid fast bacilli. At the same time, we recruited household
contacts living in the same house with pulmonary TB patients. Moreover, community controls
were randomly selected and recruited from catchment areas of selected health centers and pre-
vious TB disease or contact with pulmonary TB patients was excluded by questionnaire.
Clinical assessment including weight, height and BCG scar examination was done for all
participants. QuantiFERON-TB Gold In-Tube (QFT-GIT) test was used to screen contacts and
controls forMtb infection as previously described [20]. Besides, chest x-ray was used to screen
for active TB in contacts and controls. Smear microscopy and culture were done for contacts
with productive cough. All TB patients were treated with anti-TB drugs for 6 months. Based on
the Ethiopian national guideline [19], contacts in this study were not offered prophylactic treat-
ment for TB. Screening for HIV infection was done according to the national guideline [21]
and only those without HIV infection were included. All participants were adults from 18–60
years; those with immunosuppressive conditions (pregnancy, diabetes and immunosuppressive
therapy like steroids) were excluded. Patients and contacts were followed-up over 12 months
with clinical examination and blood sample collection at entry, 6 and 12 months. In controls,
blood samples were collected at entry. Baseline blood samples were collected from patients be-
fore they started treatment. Laboratory analysis was done at Armauer Hansen Research Insti-
tute (AHRI).
Whole Blood Assay
Heparinized blood sample was diluted to a final concentration of 1:10 with RPMI 1640 medi-
um containing L-glutamine (Sigma) supplemented with penicillin, 100 U/ml and streptomycin,
100 μg/ml (Sigma). E6C10 and Rv2031 were used to stimulate blood samples at a final concen-
tration of 10 μg/ml. For positive and negative controls, instead of E6C10 and Rv2031, PHA at
10 μg/ml (Sigma) and RPMI 1640 media were used, respectively. After 48 hours of incubation
at 37°C with 5% CO2, supernatants were harvested and stored at -80°C until ELISA was done.
Cytokine ELISA
The levels of IFN-γ, TNF-α and IL-10 were measured using Ready-Set-Go! cytokine ELISA kits
(eBioscience, USA). The detection limits of these kits were 4–500 pg/ml (IFN-γ and TNF-α)
and 2–300 pg/ml (IL-10). ELISA was done according to the manufacturer’s instructions. Brief-
ly, corning costar 96-well ELISA plates were coated overnight with anti-human IFN-γ, TNF-α,
or IL-10 capture antibodies at 4°C. Plates were blocked with assay diluent for 1 hour at room
temperature (RT). Standards and samples were added and incubated for 2 hours at RT. Assay
diluent was added in two wells instead of samples to subtract for backgrounds. Detection anti-
bodies were added and incubated for 1 hour at RT. This was followed by avidin-horseradish
peroxidase incubation for 30 minutes at RT. Plates were washed 5 times with PBS containing
5% Tween 20 after each reaction; after enzyme incubation, plates were washed 7 times. Color
was developed using 3, 30, 5, 50-tetramethylbenzidine substrate and after 15 minutes of incuba-
tion at RT, reaction was stopped using 2N sulfuric acid. Plates were read at 450 nm wave length
and sample OD values were interpolated with a four-parameter curve-fit using the standards.
Data analysis
Data points of negative control wells were subtracted from antigen stimulated data points to
adjust for non-specific responses. Values below the detection limits of each cytokine were as-
sumed to represent non-responders and set to ‘1’. Non-parametric tests were used to compare
Cytokine Response to Rv2031 in Human Cohorts
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groups. Spearman’s correlation was used to investigate the correlation between E6C10 and
Rv2031 specific cytokine responses. Kruskal-Wallis test with Dunn’s multiple comparisons was
used to compare cytokine responses among TB patients, contacts and controls at baseline.
Mann-Whitney U-test was used to compare cytokine responses between patients and contacts
at 6 and 12 months. Freidman test with Dunn’s multiple comparisons was used to compare cy-
tokine levels over 12 months in patients and contacts. P-values less than 0.05 were considered
statistically significant. GraphPad Prism version 6.00 for Windows (GraphPad Software, La
Jolla California USA, http://www.graphpad.com) was used for data analysis.
Ethics statement
The study protocol was approved by the Institutional Review Board of Aklilu Lemma Institute
of Pathobiology, the AHRI/ALERT Ethics Review Committee, the National Research Ethics
Review Committee from Ethiopia and the Regional Committees for Medical and Health Re-
search Ethics, South-East Norway (Regionale Komiteer for Medisinsk og Helsefaglig For-
skningsetikk, Sør-Øst) from Norway. Written informed consent was obtained from each
participant before inclusion into the study.
Results
Socio-demographic characteristics of study participants
A total of 147 smear positive pulmonary TB patients, 148 household contacts and 68 commu-
nity controls were included in this study. There was no significant difference in the mean age
and the proportion of those with BCG scar among the three groups. Besides, no significant as-
sociations between levels of cytokines and BCG scar were observed in all the groups. Patients,
however, had significantly lower body mass index compared to both contacts and controls
(P<0.001) (Table 1). In contacts, the median duration of exposure to TB patients was 12 (IQR:
4–24) weeks. Furthermore, the median daily exposure was 12 (IQR: 7.25–13) hours. In con-
tacts, no significant association was observed between total or daily average duration of expo-
sure to TB patients and QFT-GIT positivity. Twenty-one contacts reported previous exposure
to a TB patient other than the patient included in the study. The proportion of QFT-GIT posi-
tivity was higher in those who reported previous exposure (86%) compared to those who had
no known exposure to TB patients other than the index patient included in this study (70%)
but this difference was not statistically significant (p = 0.26).
Table 1. Socio-demographic characteristics of study participants.
Characteristics Patients Contacts Controls p-value
Mean age in years 29.4 32.0 32.4 0.13
Proportion of males (%) 58.5 44.5 47.1 0.05
Mean BMI* 17.9 21.1 22.4 <0.001
Proportion with BCG scar (%) 28.1 37.0 35.3 0.36
QFT-GIT positive (%) NA 73.2 54.4 0.005
* Mean body mass index (weight in kilograms divided by height in meters squared)
NA = data not available for all patients
doi:10.1371/journal.pone.0124134.t001
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Cytokine responses to Rv2031 in contacts and controls stratified by
QFT-GIT test result
At baseline, 54.4% and 73.2% of controls and contacts were QFT-GIT positive, respectively
(Table 1). Rv2031-specific IFN-γ, TNF-α and IL-10 responses were comparable in QFT-GIT
positive and negative contacts and controls. We, therefore, included all contacts and controls
for further analysis.
IFN-γ response to Rv2031 at baseline, 6 and 12 months
Figs 1 and 2 present IFN-γ response to Rv2031. At baseline, controls had a significantly higher
IFN-γ response compared to contacts and untreated patients (P<0.0001). However, in contacts
and treated patients, IFN-γ response significantly increased at 12 months compared to its levels
at baseline and 6 months (p<0.0001).
Fig 1. Comparison of IFN-γ response to Rv2031 among groups at baseline, 6 and 12months. IFN-γ response at baseline (a), 6 months (b) and
12 months (c) following whole blood stimulation with Rv2031 for 48 hours. Filled circles represent patients, filled diamonds represent contacts and filled
triangles represent controls. Results are individual responses and cytokine levels are expressed as log10 pg/ml. Horizontal bars are medians. Kruskal-Wallis
test with Dunn’s multiple comparisons (a) and Mann-Whitney test (b and c) were used to compare groups. ****p<0.0001.
doi:10.1371/journal.pone.0124134.g001
Fig 2. Changes in IFN-γ response to Rv2031 over 12 months in patients and contacts. IFN-γ response over 12 months in patients (a) and contacts (b)
following whole blood stimulation with Rv2031 for 48 hours. Filled circles represent baseline levels, filled diamonds represent 6 month levels and filled
triangles represent 12 month levels. Results are individual responses and cytokine levels are expressed as log10 pg/ml. Horizontal bars are medians.
Freidman test with Dunn’s multiple comparisons was used to compare IFN-γ response over time. ****p<0.0001.
doi:10.1371/journal.pone.0124134.g002
Cytokine Response to Rv2031 in Human Cohorts
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TNF-α response to Rv2031 at baseline, 6 and 12 months
TNF-α response to Rv2031 is summarized in Figs 3 and 4. At baseline, controls had a signifi-
cantly higher TNF-α response to Rv2031 compared to contacts and untreated patients
(p<0.0001). Besides, untreated patients had significantly higher TNF-α response compared to
contacts (p<0.001). In treated patients, TNF-α response was significantly higher at 12 months
compared to both baseline and 6 month levels (p<0.0001). In contacts, TNF-α response was
significantly higher at 6 months compared to its baseline response (p<0.001) and at 12 months
compared to both baseline and 6 month levels (p<0.0001).
IL-10 response to Rv2031 at baseline, 6 and 12 months
Figs 5 and 6 present IL-10 response to Rv2031. At baseline, controls had a significantly higher
IL-10 response compared to untreated patients (p<0.001) and contacts (P<0.0001). Besides,
untreated patients had significantly higher IL-10 response compared to contacts (p<0.0001).
In contacts and treated patients, IL-10 significantly increased at 12 months compared to its
level at baseline and 6 months (p<0.0001).
Fig 3. Comparison of TNF-α response to Rv2031 among groups at baseline, 6 and 12months. TNF-α response at baseline (a), 6 months (b) and
12 months (c) following whole blood stimulation with Rv2031 for 48 hours. Filled circles represent patients, filled diamonds represent contacts and filled
triangles represent controls. Results are individual responses and cytokine levels are expressed as log10 pg/ml. Horizontal bars are medians. Kruskal-Wallis
test with Dunn’s multiple comparisons (a) and Mann-Whitney test (b and c) were used to compare groups. ***p<0.001, ****p<0.0001.
doi:10.1371/journal.pone.0124134.g003
Fig 4. Changes in TNF-α response to Rv2031 over 12 months in patients and contacts. TNF-α response over 12 months in patients (a) and contacts (b)
following whole blood stimulation with Rv2031 for 48 hours. Filled circles represent baseline levels, filled diamonds represent 6 month levels and filled
triangles represent 12 month levels. Results are individual responses and cytokine levels are expressed as log10 pg/ml. Horizontal bars are medians.
Freidman test with Dunn’s multiple comparisons was used to compare TNF-α response over time. ***p<0.001, ****p<0.0001.
doi:10.1371/journal.pone.0124134.g004
Cytokine Response to Rv2031 in Human Cohorts
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Comparison of baseline IFN-γ/IL-10 and TNF-α/IL-10 ratios among
groups
Baseline IFN-γ/IL-10 ratio was significantly lower in untreated patients compared to both con-
tacts and controls (p<0.0001) (Fig 7). Similarly, baseline TNF-α/IL-10 ratio was significantly
lower in untreated patients compared to contacts (p = 0.03) and controls (p<0.0001). Besides,
controls had higher TNF-α/IL-10 ratio compared to contacts (p<0.01) (Fig 8). In contacts and
treated patients, IFN-γ/IL-10 and TNF-α/IL-10 ratios increased over 12 months and the in-
crease in TNF-α/IL-10 ratio was significant in both groups (p<0.01) (data not shown).
IFN-γ, TNF-α and IL-10 responses to E6C10 at baseline, 6 and
12 months
At baseline, contacts had significantly lower IFN-γ, TNF-α and IL-10 compared to both un-
treated patients and controls (p<0.01) whereas untreated patients and controls had compara-
ble cytokine levels (Fig 9). No significant change in the cytokine response to E6C10 was
observed in patients after treatment (Fig 10); in contrast, contacts had significantly increased
Fig 5. Comparison of IL-10 response to Rv2031 among groups at baseline, 6 and 12months. IL-10 response at baseline (a), 6 months (b) and
12 months (c) following whole blood stimulation with Rv2031 for 48 hours. Filled circles represent patients, filled diamonds represent contacts and filled
triangles represent controls. Results are individual responses and cytokine levels are expressed as log10 pg/ml. Horizontal bars are medians. Kruskal-Wallis
test with Dunn’s multiple comparisons (a) and Mann-Whitney test (b and c) were used to compare groups. ***p<0.001, ****p<0.0001.
doi:10.1371/journal.pone.0124134.g005
Fig 6. Changes in IL-10 responses to Rv2301 over 12 months in patients and contacts. IL-10 response over 12 months in patients (a) and contacts (b)
following whole blood stimulation with Rv2031 for 48 hours. Filled circles represent baseline levels, filled diamonds represent 6 month levels and filled
triangles represent 12 month levels. Results are individual responses and cytokine levels are expressed as log10 pg/ml. Horizontal bars are medians.
Freidman test with Dunn’s multiple comparisons was used to compare IL-10 response over time. ****p<0.0001.
doi:10.1371/journal.pone.0124134.g006
Cytokine Response to Rv2031 in Human Cohorts
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IFN-γ, TNF-α and IL-10 responses at 6 and 12 months compared to the corresponding base-
line responses (p<0.01) (Fig 11).
Correlation between E6C10 and Rv2031 induced cytokines
Correlations between E6C10 and Rv2031 specific cytokine responses were analyzed at baseline
and there was a significant and positive correlation for each cytokine in the three groups
(Table 2). The correlation for each cytokine in controls was relatively strong. Besides, the corre-
lation for IFN-γ as well as IL-10 remained significant at 6 and 12 months but for TNF-α, there
was no significant correlation at 12 months both in patients and contacts.
Discussion
In this study, we showed that the levels of both pro-(IFN-γ, TNF-α) and anti-inflammatory
(IL-10) cytokines against the latency antigen Rv2031 were significantly higher in community
controls compared to untreated TB patients and their contacts. Furthermore, in patients and
contacts, all cytokines significantly increased at 12 months and became comparable with the
corresponding levels in controls.
In this study, controls had a strong Rv2031-specific IFN-γ response in agreement with a
previous observation from Ethiopia and The Gambia [14]. Similarly, in a non-endemic setting,
previously exposed contacts had strong IFN-γ response to latency antigens compared to
Fig 8. Comparison of TNF-α/IL-10 ratio among groups at baseline, 6 and 12 months. TNF-α/IL-10 ratio at baseline (a), 6 months (b) and 12 months (c)
following whole blood stimulation with Rv2031 for 48 hours. Filled circles represent patients, filled diamonds represent contacts and filled triangles represent
controls. Results are individual responses. Horizontal bars are medians. Kruskal-Wallis test with Dunn’s multiple comparisons (a) and Mann-Whitney test (b
and C) were used to compare groups. *p = 0.03, **p<0.01, ****p<0.0001.
doi:10.1371/journal.pone.0124134.g008
Fig 7. Comparison of IFN-γ/IL-10 ratio among groups at baseline, 6 and 12months. IFN-γ/IL-10 ratio at baseline (a), 6 months (b) and 12 months (c)
following whole blood stimulation with Rv2031 for 48 hours. Filled circles represent patients, filled diamonds represent contacts and filled triangles represent
controls. Results are individual responses. Horizontal bars are medians. Kruskal-Wallis test with Dunn’s multiple comparisons (a) and Mann-Whitney test (b
and C) were used to compare groups. ****p<0.0001.
doi:10.1371/journal.pone.0124134.g007
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untreated TB patients [22]. On the other hand, investigators from The Netherlands found com-
parable IFN-γ response to Rv2031 in untreated TB patients and individuals with latent TB in-
fection [23]; however, it is not clear if the Dutch study included those with recent or past
exposure. In our study, both recently exposed contacts and untreated TB patients had low IFN-
γ response to Rv2031. In endemic settings, considering the high exposure and TB infection
rates, community controls could safely be assumed to have a protective immunity as opposed
to untreated TB patients who failed to control the infection [14] and therefore, a high IFN-γ re-
sponse to Rv2031 in controls is suggestive of protective immunity against TB in this group. In
addition to increased IFN-γ response as previously reported [14], we observed a significantly
higher baseline TNF-α and IL-10 responses to Rv2031 in controls compared to untreated pa-
tients and contacts. These data further suggest that cytokines other than IFN-γ are induced by
Rv2031 during latent TB infection and may contribute towards protection against progression
of TB infection. Moreover, we have measured IFN-γ, TNF-α and Il-10 responses against
E6C10, antigens believed to be specific toMtb complex, for comparison and the results showed
a significant and positive correlation between E6C10 and Rv2031 specific cytokine responses
especially in controls suggesting that cytokine responses to Rv2031 areMtb complex specific.
Put together, our data suggest that IFN-γ, TNF-α and IL-10 against Rv2031 could be poten-
tial biomarkers of protective immunity in those with latent TB infection. Furthermore, in a
mouse model, it was observed that long term protection following vaccination with BCG over-
expressing Rv2031 [9] and DNA containing Rv2031 [24] were associated with a significant
Fig 9. Comparison of baseline cytokine responses to E6C10 among groups. Baseline IFN-γ (a), TNF-α (b) and IL-10 (c) responses to E6C10 in
patients, contacts and controls following whole blood stimulation for 48 hours. Filled circles represent patients, filled diamonds represent contacts and filled
triangles represent controls. Results are individual responses and cytokine levels are expressed as log10 pg/ml. Horizontal bars are medians. Kruskal-Wallis
test with Dunn’s multiple comparisons was used to compare groups. **p<0.01, ****p<0.0001.
doi:10.1371/journal.pone.0124134.g009
Fig 10. Changes in cytokine responses to E6C10 over 12 months in patients. IFN-γ (a), TNF-α (b) and IL-10 (c) responses to E6C10 in patients at
baseline, 6 and 12 months following whole blood stimulation with E6C10 for 48 hours. Filled circles represent baseline levels, filled diamonds represent
6 month levels and filled triangles represent 12 month levels. Results are individual responses and cytokine levels are expressed as log10 pg/ml. Horizontal
bars are medians. Freidman test with Dunn’s multiple comparisons was used to compare cytokine levels overtime.
doi:10.1371/journal.pone.0124134.g010
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increase in IFN-γ response to Rv2031. Hence, our data together with previous observations in
humans and animal models suggest the potential of Rv2031 as a vaccine candidate.
Contacts and treated patients had a significant increase in the levels of Rv2031 specific IFN-
γ, TNF-α and IL-10 over 12 months. In agreement with our observation for IFN-γ, it was previ-
ously reported that untreated TB patients had low Rv2031 specific IFN-γ response followed by
a significant increase after chemotherapy [25]. Similarly, in a murine model, investigators ob-
served increased IFN-γ response to Rv2031 in the later stages of infection [8]. The low cytokine
response during clinical TB followed by a strong cytokine response after chemotherapy in pa-
tients suggests the recovery of the immune response accompanied by bacterial reduction and
this could further augment infection control and probably prevent relapse. On the other hand,
the low cytokine response in contacts during early infection followed by a strong cytokine re-
sponse after 6 months without prophylactic treatment may suggest the transition to latentMtb
Fig 11. Changes in cytokine responses to E6C10 over 12 months in contacts. IFN-γ (a), TNF-α (b) and IL-10 (c) responses to E6C10 in contacts at
baseline, 6 and 12 months following whole blood stimulation with E6C10 for 48 hours. Filled circles represent baseline levels, filled diamonds represent
6 month levels and filled triangles represent 12 month levels. Results are individual responses and cytokine levels are expressed as log10 pg/ml. Horizontal
bars are medians. Freidman test with Dunn’s multiple comparisons was used to compare cytokine levels overtime. **p<0.01, ****p<0.0001.
doi:10.1371/journal.pone.0124134.g011
Table 2. Correlation between E6C10 and Rv2031 specific IFN-γ, TNF-α and IL-10.
Patients Contacts Controls
IFN-γ (Rv2031 vs. E6C10)
Baseline 0.36** 0.41** 0.65**
6 months 0.35** 0.36**
12 months 0.43** 0.37**
TNF-α (Rv2031 vs. E6C10)
Baseline 0.44** 0.34** 0.79**
6 months 0.59** 0.41**
12 months 0.19 0.18
Il-10 (Rv2031 vs. E6C10)
Baseline 0.53** 0.62** 0.70**
6 months 0.69** 0.63**
12 months 0.36** 0.54**
Vs. versus
**p<0.01
For each group, the correlation between E6C10 and Rv2031 speciﬁc IFN-γ, TNF-α and IL-10 responses
were investigated using Spearman’s correlation and at baseline, Rv2031-speciﬁc cytokine responses were
positively and signiﬁcantly correlated with the corresponding cytokine responses to E6C10.
doi:10.1371/journal.pone.0124134.t002
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infection with reduction of bacteria and development of protective immunity. Besides, recent
infection, at least in some of the contacts, might account for low cytokine response. Our data
suggest that cytokine response to Rv2031 is dynamic with low response in recent exposure/in-
fection or clinical TB followed by increased cytokine levels probably associated with increased
expression of Rv2031 during latent TB infection [5]. Supporting this notion, a concurrent in-
crease in the expression of Th1 immunity and Rv2031 together with other latency antigens was
observed in a mouse model [26]. Rv2031 is considered to be an important antigen that main-
tains protein stability and hence long term viability ofMtb in macrophages [5, 27] and its in-
creased expression during latency might be crucial forMtb survival.
Further analysis of cytokine ratios revealed a stage-specific trend in which both IFN-γ/IL-10
and TNF-α/IL-10 ratios were lowest in untreated patients and highest in controls with a signifi-
cant difference among the three groups. Although TNF-α and IL-10 were significantly higher
in patients compared to contacts, TNF-α/IL-10 ratio was significantly lower in patients com-
pared to contacts. Besides, IFN-γ/IL-10 and TNF-α/IL-10 ratios increased over time in treated
patients and contacts. Taken together, these data suggest that apart from the absolute amount
of each cytokine, the balance between pro-inflammatory (IFN-γ and TNF-α) and anti-inflam-
matory (IL-10) cytokine responses to Rv2031 could determine the outcome of infection [16].
We did not find any significant difference in the immune response to Rv2031 in QFT-GIT
positive and negative contacts and controls. This might be because the infection is either too
early to develop cytokine response to Rv2031 (contacts) or too remote to be detected by
QFT-GIT (controls). Supporting the later assertion, reversions to QFT-GIT negative in
QFT-GIT positive healthy individuals over time has been reported as a common event [28, 29].
In addition, the strong immune response in controls in this study seems unlikely to be related
to previous BCG vaccination as our data suggests. Generally, immune response to BCG wanes
after 15 years and all our study participants were adults. Moreover, whereas one study reported
a strong IFN-γ response in BCG vaccinees [25], a minimal T-cell response against Rv2031 in
BCG vaccinated population was observed in another study [23]. Similarly, a study from The
Gambia reported lack of IFN-γ response in BCG vaccinated infants [12].
The present study showed that during naturalMtb infection in humans in endemic settings,
contacts with recent exposure and /or infection and patients with clinical TB have low baseline
cytokine response to Rv2031 followed by a significant and sustained increase of both pro- and
anti-inflammatory cytokines after 6 months. A high IFN-γ, TNF-α and IL-10 against Rv2031
during latent TB infection suggests their role as protective markers of TB in humans. Taken to-
gether, the findings of this study suggest the potential of IFN-γ, TNF-α and IL-10 against
Rv2031 as biomarkers of the host response toMtb during convalescence from, and the absence
of, active tuberculosis.
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